Ask the Expert: What’s the challenge that HCPs present in biologics manufacturing?

Learn from LS Process Validation Expert, Nadia Oueslati, Ph.D. from our Biodevelopment Center France, how our customer has reduced the presence of Host Cell Proteins (HPCs) in the bioreactor harvest in one month, prior to a production run that was going to supply drug substance for a scheduled Phase I clinical trial.

The goal for this customer was to reduce the level of HCPs to less than 300 ppm and ensure clarification of the entire 2000L harvest.  

Are you a small-sized biotech?                                                                                                                                    Learn about our Plug & Play Upstream Development Service at http://ms.spr.ly/6055eCEZz...  

BioReliance® End-to-End Solutions

BioReliance® End-to-End Solutions is an adaptable CDMO partner for small biotechs and start-ups needing to develop and commercialize biologics. We do this by balancing speed, risk and cost through custom solutions, by leveraging our bioprocessing technologies and process development expertise, and by allowing our clients to transfer their process and knowledge to their end point at any step of their drug development. To learn more, please visit http://ms.spr.ly/6056eCEZM...